YAP and TAZ: A nexus for Hippo signaling and beyond

Trends in Cell Biology

Volumn 25, Issue 9, 2015, Pages 499-513

  Hansen, Carsten Gram ^a,b   Moroishi, Toshiro ^a,b   Guan, Kun Liang ^a,b  

^a San Diego   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Extracellular matrix; Notch; Primary cilia; Regeneration; Stem cells; Wnt

Indexed keywords

BONE MORPHOGENETIC PROTEIN; EPIDERMAL GROWTH FACTOR; G PROTEIN COUPLED RECEPTOR; LARGE TUMOR SUPPRESSOR PROTEIN; PROTEIN; TRANSCRIPTIONAL COACTIVATOR WITH PDZ BINDING DOMAIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; YES ASSOCIATED PROTEIN; HIPPO PROTEIN, HUMAN; PHOSPHOPROTEIN; PROTEIN SERINE THREONINE KINASE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TAZ PROTEIN, HUMAN; TRANSCRIPTION FACTOR; YAP1 (YES-ASSOCIATED) PROTEIN, HUMAN;

CELL DIFFERENTIATION; CELL INTERACTION; CELL JUNCTION; CELL NUCLEUS; CELL ORGANELLE; CELL PROLIFERATION; CELL SHAPE; CYTOPLASM; CYTOSKELETON; HIPPO PATHWAY; HUMAN; INTESTINE; MECHANOTRANSDUCTION; NONHUMAN; NOTCH SIGNALING; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; WNT SIGNALING PATHWAY; ANIMAL; METABOLISM; PHYSIOLOGICAL STRESS; PHYSIOLOGY; TRANSCRIPTION INITIATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; HUMANS; INTESTINES; PHOSPHOPROTEINS; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; STRESS, PHYSIOLOGICAL; TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION;

EID: 84940467318     PISSN: 09628924     EISSN: 18793088     Source Type: Journal    
DOI: 10.1016/j.tcb.2015.05.002     Document Type: Review

References (202)

1. Pan D. The hippo signaling pathway in development and cancer. Dev. Cell 2010, 19:491-505.
2. Oh H., Irvine K.D. Yorkie: the final destination of Hippo signaling. Trends Cell Biol. 2010, 20:410-417.
3. Varelas X. The Hippo pathway effectors TAZ and YAP in development, homeostasis and disease. Development 2014, 141:1614-1626.
4. Moroishi T., et al. The emerging roles of YAP and TAZ in cancer. Nat. Rev. Cancer 2015, 15:73-79.
5. Harvey K.F., et al. The Hippo pathway and human cancer. Nat. Rev. Cancer 2013, 13:246-257.
6. Johnson R., Halder G. The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment. Nat Rev. Drug Discov. 2014, 13:63-79.
7. Yu F.X., et al. Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell 2012, 150:780-791.
8. Mo J.S., et al. Regulation of the Hippo-YAP pathway by protease-activated receptors (PARs). Genes Dev. 2012, 26:2138-2143.
9. Miller E., et al. Identification of serum-derived sphingosine-1-phosphate as a small molecule regulator of YAP. Chem. Biol. 2012, 19:955-962.
10. Bao Y., et al. A cell-based assay to screen stimulators of the Hippo pathway reveals the inhibitory effect of dobutamine on the YAP-dependent gene transcription. J. Biochem. 2011, 150:199-208.
11. Liu G., et al. Kaposi sarcoma-associated herpesvirus promotes tumorigenesis by modulating the Hippo pathway. Oncogene 2014, Published online September 8, 2014. 10.1038/onc.2014.281.
12. Yu F.X., et al. Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP. Cancer Cell 2014, 25:822-830.
13. Feng X., et al. Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. Cancer Cell 2014, 25:831-845.
14. Azzolin L., et al. Role of TAZ as mediator of Wnt signaling. Cell 2012, 151:1443-1456.
15. Varelas X., et al. The Hippo pathway regulates Wnt/β-catenin signaling. Dev. Cell 2010, 18:579-591.
16. Barry E.R., et al. Restriction of intestinal stem cell expansion and the regenerative response by YAP. Nature 2013, 493:106-110.
17. Konsavage W.M., et al. Wnt/β-catenin signaling regulates Yes-associated protein (YAP) gene expression in colorectal carcinoma cells. J. Biol. Chem. 2012, 287:11730-11739.
18. Hiemer S.E., et al. The transcriptional regulators TAZ and YAP direct transforming growth factor beta-induced tumorigenic phenotypes in breast cancer cells. J. Biol. Chem. 2014, 289:13461-13474.
19. Varelas X., et al. TAZ controls Smad nucleocytoplasmic shuttling and regulates human embryonic stem-cell self-renewal. Nat. Cell Biol. 2008, 10:837-848.
20. Serrano I., et al. Inactivation of the Hippo tumour suppressor pathway by integrin-linked kinase. Nat. Commun. 2013, 4:2976.
21. Zhang J., et al. YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway. Nat. Cell Biol. 2009, 11:1444-1450.
22. Fan R., et al. Regulation of Hippo pathway by mitogenic growth factors via phosphoinositide 3-kinase and phosphoinositide-dependent kinase-1. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:2569-2574.
23. Reddy B.V., Irvine K.D. Regulation of Hippo signaling by EGFR-MAPK signaling through Ajuba family proteins. Dev. Cell 2013, 24:459-471.
24. Haskins J.W., et al. Neuregulin 1-activated ERBB4 interacts with YAP to induce Hippo pathway target genes and promote cell migration. Sci. Signal. 2014, 7:ra116.
25. Li Y., et al. Genome-wide analysis of N1ICD/RBPJ targets in vivo reveals direct transcriptional regulation of Wnt, SHH, and Hippo pathway effectors by Notch1. Stem Cells 2012, 30:741-752.
26. Tschaharganeh D.F., et al. Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma. Gastroenterology 2013, 144:1530-1542.
27. Camargo F.D., et al. YAP1 increases organ size and expands undifferentiated progenitor cells. Curr. Biol. 2007, 17:2054-2060.
28. Rayon T., et al. Notch and Hippo converge on cdx2 to specify the trophectoderm lineage in the mouse blastocyst. Dev. Cell 2014, 30:410-422.
29. Hergovich A. Regulation and functions of mammalian LATS/NDR kinases: looking beyond canonical Hippo signalling. Cell Biosci. 2013, 3:32.
30. Zhou D., et al. Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell 2009, 16:425-438.
31. Yin F., et al. Spatial organization of Hippo signaling at the plasma membrane mediated by the tumor suppressor Merlin/NF2. Cell 2013, 154:1342-1355.
32. Li Q., et al. The conserved Misshapen-Warts-Yorkie pathway acts in enteroblasts to regulate intestinal stem cells in Drosophila. Dev. Cell 2014, 31:291-304.
33. Ma B., et al. Hypoxia regulates Hippo signalling through the SIAH2 ubiquitin E3 ligase. Nat. Cell Biol. 2015, 17:95-103.
34. Lignitto L., et al. Proteolysis of MOB1 by the ubiquitin ligase praja2 attenuates Hippo signalling and supports glioblastoma growth. Nat. Commun. 2013, 4:1822.
35. DeRan M., et al. Energy stress regulates Hippo-YAP signaling involving AMPK-mediated regulation of Angiomotin-like 1 protein. Cell Rep. 2014, 9:495-503.
36. Salah Z., et al. Negative regulation of the Hippo pathway by E3 ubiquitin ligase ITCH is sufficient to promote tumorigenicity. Cancer Res. 2011, 71:2010-2020.
37. Bae S.J., et al. NEDD4 controls intestinal stem cell homeostasis by regulating the Hippo signalling pathway. Nat. Commun. 2015, 6:6314.
38. Heidary Arash E., et al. Arhgef7 promotes activation of the Hippo pathway core kinase Lats. EMBO J. 2014, 33:2997-3011.
39. Pearson H.B., et al. SCRIB expression is deregulated in human prostate cancer, and its deficiency in mice promotes prostate neoplasia. J. Clin. Invest. 2011, 121:4257-4267.
40. Liu-Chittenden Y., et al. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev. 2012, 26:1300-1305.
41. Cockburn K., et al. The Hippo pathway member Nf2 is required for inner cell mass specification. Curr. Biol. 2013, 23:1195-1201.
42. Zhao B., et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 2007, 21:2747-2761.
43. Zhao B., et al. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev. 2008, 22:1962-1971.
44. Kim N.G., et al. E-cadherin mediates contact inhibition of proliferation through Hippo signaling-pathway components. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:11930-11935.
45. Cordenonsi M., et al. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell 2011, 147:759-772.
46. Baumgartner R., et al. The WW domain protein Kibra acts upstream of Hippo in Drosophila. Dev. Cell 2010, 18:309-316.
47. Genevet A., et al. Kibra is a regulator of the Salvador/Warts/Hippo signaling network. Dev. Cell 2010, 18:300-308.
48. Yu J., et al. Kibra functions as a tumor suppressor protein that regulates Hippo signaling in conjunction with Merlin and Expanded. Dev. Cell 2010, 18:288-299.
49. Hirate Y., et al. Polarity-dependent distribution of Angiomotin localizes Hippo signaling in preimplantation embryos. Curr. Biol. 2013, 23:1181-1194.
50. DCAF1-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus. Cancer Cell 2014, 26:48-60.
51. Das Thakur M., et al. Ajuba LIM proteins are negative regulators of the Hippo signaling pathway. Curr. Biol. 2010, 20:657-662.
52. Rauskolb C., et al. Cytoskeletal tension inhibits Hippo signaling through an Ajuba-Warts complex. Cell 2014, 158:143-156.
53. Zhao B., et al. Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein. Genes Dev. 2011, 25:51-63.
54. Chan S.W., et al. Hippo pathway-independent restriction of TAZ and YAP by Angiomotin. J. Biol. Chem. 2011, 286:7018-7026.
55. Wang W., et al. Angiomotin-like proteins associate with and negatively regulate YAP1. J. Biol. Chem. 2011, 286:4364-4370.
56. Leung C.Y., Zernicka-Goetz M. Angiomotin prevents pluripotent lineage differentiation in mouse embryos via Hippo pathway-dependent and -independent mechanisms. Nat. Commun. 2013, 4:2251.
57. Liu X., et al. PTPN14 interacts with and negatively regulates the oncogenic function of YAP. Oncogene 2013, 32:1266-1273.
58. Wang W., et al. PTPN14 is required for the density-dependent control of YAP1. Genes Dev. 2012, 26:1959-1971.
59. Schlegelmilch K., et al. Yap1 acts downstream of α-catenin to control epidermal proliferation. Cell 2011, 144:782-795.
60. Sudol M., Harvey K.F. Modularity in the Hippo signaling pathway. Trends Biochem. Sci. 2010, 35:627-633.
61. Mana-Capelli S., et al. Angiomotins link F-actin architecture to Hippo pathway signaling. Mol. Biol. Cell 2014, 25:1676-1685.
62. Adler J.J., et al. Serum deprivation inhibits the transcriptional co-activator YAP and cell growth via phosphorylation of the 130-kDa isoform of Angiomotin by the LATS1/2 protein kinases. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:17368-17373.
63. Dai X., et al. Phosphorylation of Angiomotin by Lats1/2 kinases inhibits F-actin binding, cell migration, and angiogenesis. J. Biol. Chem. 2013, 288:34041-34051.
64. Yi C., et al. The p130 isoform of Angiomotin is required for Yap-mediated hepatic epithelial cell proliferation and tumorigenesis. Sci. Signal. 2013, 6:ra77.
65. Chan S.W., et al. WW domain-mediated interaction with Wbp2 is important for the oncogenic property of TAZ. Oncogene 2011, 30:600-610.
66. Zhang X., et al. Wbp2 cooperates with Yorkie to drive tissue growth downstream of the Salvador-Warts-Hippo pathway. Cell Death Differ. 2011, 18:1346-1355.
67. Sansores-Garcia L., et al. Mask is required for the activity of the Hippo pathway effector Yki/YAP. Curr. Biol. 2013, 23:229-235.
68. Sidor C.M., et al. Mask proteins are cofactors of Yorkie/YAP in the Hippo pathway. Curr. Biol. 2013, 23:223-228.
69. Koontz L.M., et al. The Hippo effector Yorkie controls normal tissue growth by antagonizing Scalloped-mediated default repression. Dev. Cell 2013, 25:388-401.
70. Zhang W., et al. VGLL4 functions as a new tumor suppressor in lung cancer by negatively regulating the YAP-TEAD transcriptional complex. Cell Res. 2014, 24:331-343.
71. Jiao S., et al. A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. Cancer Cell 2014, 25:166-180.
72. Vassilev A., et al. TEAD/TEF transcription factors utilize the activation domain of YAP65, a Src/Yes-associated protein localized in the cytoplasm. Genes Dev. 2001, 15:1229-1241.
73. Ota M., Sasaki H. Mammalian Tead proteins regulate cell proliferation and contact inhibition as transcriptional mediators of Hippo signaling. Development 2008, 135:4059-4069.
74. Mo J.S., et al. The Hippo signaling pathway in stem cell biology and cancer. EMBO Rep. 2014, 15:642-656.
75. Oh H., et al. Yorkie promotes transcription by recruiting a histone methyltransferase complex. Cell Rep. 2014, 8:449-459.
76. Qing Y., et al. The Hippo effector Yorkie activates transcription by interacting with a histone methyltransferase complex through Ncoa6. Elife 2014, 3:e02564.
77. Skibinski A., et al. The Hippo transducer TAZ interacts with the SWI/SNF complex to regulate breast epithelial lineage commitment. Cell Rep. 2014, 6:1059-1072.
78. Oh H., et al. Genome-wide association of Yorkie with chromatin and chromatin-remodeling complexes. Cell Rep. 2013, 3:309-318.
79. Beyer T.A., et al. Switch enhancers interpret TGF-β and Hippo signaling to control cell fate in human embryonic stem cells. Cell Rep. 2013, 5:1611-1624.
80. Kim M., et al. Transcriptional co-repressor function of the Hippo pathway transducers YAP and TAZ. Cell Rep. 2015, 11:270-282.
81. Mori M., et al. Hippo signaling regulates microprocessor and links cell-density-dependent miRNA biogenesis to cancer. Cell 2014, 156:893-906.
82. Chaulk S.G., et al. The Hippo pathway effectors TAZ/YAP regulate Dicer expression and microRNA biogenesis through Let-7. J. Biol. Chem. 2014, 289:1886-1891.
83. 3K-TOR pathways by suppressing PTEN via miR-29. Nat. Cell Biol. 2012, 14:1322-1329.
84. Piccolo S., et al. The biology of YAP/TAZ: Hippo signaling and beyond. Physiol. Rev. 2014, 94:1287-1312.
85. Clevers H., et al. Stem cell signaling. An integral program for tissue renewal and regeneration: Wnt signaling and stem cell control. Science 2014, 346:1248012.
86. Imajo M., et al. A molecular mechanism that links Hippo signalling to the inhibition of Wnt/β-catenin signalling. EMBO J. 2012, 31:1109-1122.
87. Azzolin L., et al. YAP/TAZ incorporation in the β-catenin destruction complex orchestrates the Wnt response. Cell 2014, 158:157-170.
88. Takahashi A., et al. SHP2 tyrosine phosphatase converts parafibromin/Cdc73 from a tumor suppressor to an oncogenic driver. Mol. Cell 2011, 43:45-56.
89. Tsutsumi R., et al. YAP and TAZ, Hippo signaling targets, act as a rheostat for nuclear SHP2 function. Dev. Cell 2013, 26:658-665.
90. Mosimann C., et al. Parafibromin/Hyrax activates Wnt/Wg target gene transcription by direct association with β-catenin/Armadillo. Cell 2006, 125:327-341.
91. Llado V., et al. Repression of intestinal stem cell function and tumorigenesis through direct phosphorylation of β-catenin and Yap by PKCζ. Cell Rep. 2015, 10:740-754.
92. Heallen T., et al. Hippo pathway inhibits Wnt signaling to restrain cardiomyocyte proliferation and heart size. Science 2011, 332:458-461.
93. Cai J., et al. The Hippo signaling pathway restricts the oncogenic potential of an intestinal regeneration program. Genes Dev. 2010, 24:2383-2388.
94. Hossain Z., et al. Glomerulocystic kidney disease in mice with a targeted inactivation of Wwtr1. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:1631-1636.
95. Zhou D., et al. Mst1 and Mst2 protein kinases restrain intestinal stem cell proliferation and colonic tumorigenesis by inhibition of Yes-associated protein (Yap) overabundance. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:E1312-E1320.
96. Imajo M., et al. Dual role of YAP and TAZ in renewal of the intestinal epithelium. Nat. Cell Biol. 2015, 17:7-19.
97. Lai D., Yang X. BMP4 is a novel transcriptional target and mediator of mammary cell migration downstream of the Hippo pathway component TAZ. Cell. Signal. 2013, 25:1720-1728.
98. Seo E., et al. SOX2 regulates YAP1 to maintain stemness and determine cell fate in the osteo-adipo lineage. Cell Rep. 2013, 3:2075-2087.
99. Haramis A.P., et al. De novo crypt formation and juvenile polyposis on BMP inhibition in mouse intestine. Science 2004, 303:1684-1686.
100. Forbes S.J., Rosenthal N. Preparing the ground for tissue regeneration: from mechanism to therapy. Nat. Med. 2014, 20:857-869.
101. Taniguchi K., et al. A gp130-Src-YAP module links inflammation to epithelial regeneration. Nature 2015, 519:57-62.
102. Massague J. TGFβ signalling in context. Nat. Rev. Mol. Cell Biol. 2012, 13:616-630.
103. Schuldiner M., et al. Effects of eight growth factors on the differentiation of cells derived from human embryonic stem cells. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:11307-11312.
104. Varelas X., et al. The Crumbs complex couples cell density sensing to Hippo-dependent control of the TGF-β-SMAD pathway. Dev. Cell 2010, 19:831-844.
105. Nallet-Staub F., et al. Cell density sensing alters TGF-β signaling in a cell-type-specific manner, independent from Hippo pathway activation. Dev. Cell 2015, 32:640-651.
106. Narimatsu M., et al. Distinct polarity cues direct Taz/Yap and TGFβ receptor localization to differentially control TGFβ-induced Smad signaling. Dev. Cell 2015, 32:652-656.
107. Lian I., et al. The role of YAP transcription coactivator in regulating stem cell self-renewal and differentiation. Genes Dev. 2010, 24:1106-1118.
108. Alarcon C., et al. Nuclear CDKs drive Smad transcriptional activation and turnover in BMP and TGF-β pathways. Cell 2009, 139:757-769.
109. Zhao R., et al. Yap tunes airway epithelial size and architecture by regulating the identity, maintenance, and self-renewal of stem cells. Dev. Cell 2014, 30:151-165.
110. Mahoney J.E., et al. The Hippo pathway effector Yap controls patterning and differentiation of airway epithelial progenitors. Dev. Cell 2014, 30:137-150.
111. Judson R.N., et al. The Hippo pathway member Yap plays a key role in influencing fate decisions in muscle satellite cells. J. Cell Sci. 2012, 125:6009-6019.
112. Lee M.J., et al. YAP and TAZ regulate skin wound healing. J. Invest. Dermatol. 2014, 134:518-525.
113. Diepenbruck M., et al. Tead2 expression levels control the subcellular distribution of Yap and Taz, zyxin expression and epithelial-mesenchymal transition. J. Cell Sci. 2014, 127:1523-1536.
114. Kim M., et al. cAMP/PKA signalling reinforces the LATS-YAP pathway to fully suppress YAP in response to actin cytoskeletal changes. EMBO J. 2013, 32:1543-1555.
115. Yu F.X., et al. Protein kinase A activates the Hippo pathway to modulate cell proliferation and differentiation. Genes Dev. 2013, 27:1223-1232.
116. Plouffe S.W., et al. Disease implications of the Hippo/YAP pathway. Trends Mol. Med. 2015, 21:212-222.
117. Park H.W., Guan K.L. Regulation of the Hippo pathway and implications for anticancer drug development. Trends Pharmacol. Sci. 2013, 34:581-589.
118. Yun C.C., Kumar A. Diverse roles of LPA signaling in the intestinal epithelium. Exp. Cell Res. 2014, 333:201-207.
119. Fukui H., et al. S1P-Yap1 signaling regulates endoderm formation required for cardiac precursor cell migration in zebrafish. Dev. Cell 2014, 31:128-136.
120. Avery K., et al. Sphingosine-1-phosphate mediates transcriptional regulation of key targets associated with survival, proliferation, and pluripotency in human embryonic stem cells. Stem Cells Dev. 2008, 17:1195-1205.
121. Nagata Y., et al. Entry of muscle satellite cells into the cell cycle requires sphingolipid signaling. J. Cell Biol. 2006, 174:245-253.
122. Komuro A., et al. WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus. J. Biol. Chem. 2003, 278:33334-33341.
123. Omerovic J., et al. Ligand-regulated association of ErbB-4 to the transcriptional co-activator YAP65 controls transcription at the nuclear level. Exp. Cell Res. 2004, 294:469-479.
124. Tomas A., et al. EGF receptor trafficking: consequences for signaling and cancer. Trends Cell Biol. 2014, 24:26-34.
125. Nishioka N., et al. The Hippo signaling pathway components Lats and Yap pattern Tead4 activity to distinguish mouse trophectoderm from inner cell mass. Dev. Cell 2009, 16:398-410.
126. Home P., et al. Altered subcellular localization of transcription factor TEAD4 regulates first mammalian cell lineage commitment. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:7362-7367.
127. Yagi R., et al. Transcription factor TEAD4 specifies the trophectoderm lineage at the beginning of mammalian development. Development 2007, 134:3827-3836.
128. Strumpf D., et al. Cdx2 is required for correct cell fate specification and differentiation of trophectoderm in the mouse blastocyst. Development 2005, 132:2093-2102.
129. Yimlamai D., et al. Hippo pathway activity influences liver cell fate. Cell 2014, 157:1324-1338.
130. Tchorz J.S., et al. Notch2 signaling promotes biliary epithelial cell fate specification and tubulogenesis during bile duct development in mice. Hepatology 2009, 50:871-879.
131. Boulter L., et al. Macrophage-derived Wnt opposes Notch signaling to specify hepatic progenitor cell fate in chronic liver disease. Nat. Med. 2012, 18:572-579.
132. Bjornson C.R., et al. Notch signaling is necessary to maintain quiescence in adult muscle stem cells. Stem Cells 2012, 30:232-242.
133. Tremblay A.M., et al. The Hippo transducer YAP1 transforms activated satellite cells and is a potent effector of embryonal rhabdomyosarcoma formation. Cancer Cell 2014, 26:273-287.
134. Watt K.I., et al. Yap is a novel regulator of C2C12 myogenesis. Biochem. Biophys. Res. Commun. 2010, 393:619-624.
135. Wang N., et al. Mechanotransduction at a distance: mechanically coupling the extracellular matrix with the nucleus. Nat. Rev. Mol. Cell Biol. 2009, 10:75-82.
136. Seguin L., et al. Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance. Trends Cell Biol. 2015, 25:234-240.
137. Gaspar P., Tapon N. Sensing the local environment: actin architecture and Hippo signalling. Curr. Opin. Cell Biol. 2014, 31:74-83.
138. Engler A.J., et al. Matrix elasticity directs stem cell lineage specification. Cell 2006, 126:677-689.
139. Zhao B., et al. Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. Genes Dev. 2012, 26:54-68.
140. Cui Y., et al. Cyclic stretching of soft substrates induces spreading and growth. Nat. Commun. 2015, 6:6333.
141. Wada K., et al. Hippo pathway regulation by cell morphology and stress fibers. Development 2011, 138:3907-3914.
142. Dupont S., et al. Role of YAP/TAZ in mechanotransduction. Nature 2011, 474:179-183.
143. Ganem N.J., et al. Cytokinesis failure triggers Hippo tumor suppressor pathway activation. Cell 2014, 158:833-848.
144. Fletcher G.C., et al. The Spectrin cytoskeleton regulates the Hippo signalling pathway. EMBO J. 2015, 34:940-954.
145. Deng H., et al. Spectrin regulates Hippo signaling by modulating cortical actomyosin activity. Elife 2015, 4:e06567.
146. Chang C., et al. A laminin 511 matrix is regulated by TAZ and functions as the ligand for the α6Bβ1 integrin to sustain breast cancer stem cells. Genes Dev. 2015, 29:1-6.
147. Kim K.M., et al. Shear stress induced by an interstitial level of slow flow increases the osteogenic differentiation of mesenchymal stem cells through TAZ activation. PLoS ONE 2014, 9:e92427.
148. Halder G., et al. Transduction of mechanical and cytoskeletal cues by YAP and TAZ. Nat. Rev. Mol. Cell Biol. 2012, 13:591-600.
149. Hong J.H., et al. TAZ, a transcriptional modulator of mesenchymal stem cell differentiation. Science 2005, 309:1074-1078.
150. Parsons J.T., et al. Cell adhesion: integrating cytoskeletal dynamics and cellular tension. Nat. Rev. Mol. Cell Biol. 2010, 11:633-643.
151. Wu D.D., et al. Matricellular protein Cyr61 bridges lysophosphatidic acid and integrin pathways leading to cell migration. J. Biol. Chem. 2014, 289:5774-5783.
152. Tang Y., et al. MT1-MMP-dependent control of skeletal stem cell commitment via a β1-integrin/YAP/TAZ signaling axis. Dev. Cell 2013, 25:402-416.
153. Kim M., et al. The MST1/2-SAV1 complex of the Hippo pathway promotes ciliogenesis. Nat. Commun. 2014, 5:5370.
154. Kang H.S., et al. Glis3 is associated with primary cilia and Wwtr1/TAZ and implicated in polycystic kidney disease. Mol. Cell. Biol. 2009, 29:2556-2569.
155. Kim J., et al. Actin remodelling factors control ciliogenesis by regulating YAP/TAZ activity and vesicle trafficking. Nat. Commun. 2015, 6:6781.
156. Czarnecki P.G., Shah J.V. The ciliary transition zone: from morphology and molecules to medicine. Trends Cell Biol. 2012, 22:201-210.
157. Battle C., et al. Intracellular and extracellular forces drive primary cilia movement. Proc. Natl. Acad. Sci. U.S.A. 2015, 112:1410-1415.
158. Fernandez L.A., et al. YAP1 is amplified and up-regulated in hedgehog-associated medulloblastomas and mediates sonic hedgehog-driven neural precursor proliferation. Genes Dev. 2009, 23:2729-2741.
159. Sang L., et al. Mapping the NPHP-JBTS-MKS protein network reveals ciliopathy disease genes and pathways. Cell 2011, 145:513-528.
160. Habbig S., et al. The ciliopathy disease protein NPHP9 promotes nuclear delivery and activation of the oncogenic transcriptional regulator TAZ. Hum. Mol. Genet. 2012, 21:5528-5538.
161. Frank V., et al. Mutations in NEK8 link multiple organ dysplasia with altered Hippo signalling and increased c-MYC expression. Hum. Mol. Genet. 2013, 22:2177-2185.
162. Briscoe J., Therond P.P. The mechanisms of hedgehog signalling and its roles in development and disease. Nat. Rev. Mol. Cell Biol. 2013, 14:416-429.
163. Sharpe H.J., et al. Regulation of the oncoprotein Smoothened by small molecules. Nat. Chem. Biol. 2015, 11:246-255.
164. Hildebrandt F., et al. Ciliopathies. N. Engl. J. Med. 2011, 364:1533-1543.
165. Kwon Y., et al. The Hippo signaling pathway interactome. Science 2013, 342:737-740.
166. Wang W., et al. Defining the protein-protein interaction network of the human Hippo pathway. Mol. Cell. Proteomics 2014, 13:119-131.
167. Couzens A.L., et al. Protein interaction network of the mammalian Hippo pathway reveals mechanisms of kinase-phosphatase interactions. Sci. Signal. 2013, 6:rs15.
168. Gilbert M.M., et al. A screen for conditional growth suppressor genes identifies the Drosophila homolog of HD-PTP as a regulator of the oncoprotein Yorkie. Dev. Cell 2011, 20:700-712.
169. Liang N., et al. Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex. J. Exp. Med. 2014, 211:2249-2263.
170. β-TRCP. Genes Dev. 2010, 24:72-85.
171. Kim Y.C., Guan K.L. mTOR: a pharmacologic target for autophagy regulation. J. Clin. Invest. 2015, 125:25-32.
172. Jewell J.L., et al. Amino acid signalling upstream of mTOR. Nat. Rev. Mol. Cell Biol. 2013, 14:133-139.
173. Justice R.W., et al. The Drosophila tumor suppressor gene warts encodes a homolog of human myotonic dystrophy kinase and is required for the control of cell shape and proliferation. Genes Dev. 1995, 9:534-546.
174. Dong J., et al. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 2007, 130:1120-1133.
175. Hilman D., Gat U. The evolutionary history of YAP and the Hippo/YAP pathway. Mol. Biol. Evol. 2011, 28:2403-2417.
176. Sebe-Pedros A., et al. Premetazoan origin of the Hippo signaling pathway. Cell Rep. 2012, 1:13-20.
177. Boggiano J.C., et al. Tao-1 phosphorylates Hippo/MST kinases to regulate the Hippo-Salvador-Warts tumor suppressor pathway. Dev. Cell 2011, 21:888-895.
178. Poon C.L., et al. The sterile 20-like kinase Tao-1 controls tissue growth by regulating the Salvador-Warts-Hippo pathway. Dev. Cell 2011, 21:896-906.
179. Huang H.L., et al. Par-1 regulates tissue growth by influencing Hippo phosphorylation status and Hippo-Salvador association. PLoS Biol. 2013, 11:e1001620.
180. Wehr M.C., et al. Salt-inducible kinases regulate growth through the Hippo signalling pathway in Drosophila. Nat. Cell Biol. 2013, 15:61-71.
181. Polesello C., et al. The Drosophila RASSF homolog antagonizes the Hippo pathway. Curr. Biol. 2006, 16:2459-2465.
182. Ribeiro P.S., et al. Combined functional genomic and proteomic approaches identify a PP2A complex as a negative regulator of Hippo signaling. Mol. Cell 2010, 39:521-534.
183. Mohseni M., et al. A genetic screen identifies an LKB1-MARK signalling axis controlling the Hippo-YAP pathway. Nat. Cell Biol. 2014, 16:108-117.
184. Praskova M., et al. Regulation of the MST1 kinase by autophosphorylation, by the growth inhibitory proteins, RASSF1 and NORE1, and by Ras. Biochem. J. 2004, 381:453-462.
185. Ikeda M., et al. Hippo pathway-dependent and -independent roles of RASSF6. Sci. Signal. 2009, 2:ra59.
186. Bossuyt W., et al. An evolutionary shift in the regulation of the Hippo pathway between mice and flies. Oncogene 2014, 33:1218-1228.
187. Cappello S., et al. Mutations in genes encoding the cadherin receptor-ligand pair DCHS1 and FAT4 disrupt cerebral cortical development. Nat. Genet. 2013, 45:1300-1308.
188. Chen C.L., et al. The apical-basal cell polarity determinant Crumbs regulates Hippo signaling in Drosophila. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:15810-15815.
189. Ling C., et al. The apical transmembrane protein Crumbs functions as a tumor suppressor that regulates Hippo signaling by binding to Expanded. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:10532-10537.
190. Robinson B.S., et al. Crumbs regulates Salvador/Warts/Hippo signaling in Drosophila via the FERM-domain protein Expanded. Curr. Biol. 2010, 20:582-590.
191. Badouel C., et al. The FERM-domain protein Expanded regulates Hippo pathway activity via direct interactions with the transcriptional activator Yorkie. Dev. Cell 2009, 16:411-420.
192. Oh H., et al. Phosphorylation-independent repression of Yorkie in Fat-Hippo signaling. Dev. Biol. 2009, 335:188-197.
193. Hamaratoglu F., et al. The tumour-suppressor genes NF2/Merlin and Expanded act through Hippo signalling to regulate cell proliferation and apoptosis. Nat. Cell Biol. 2006, 8:27-36.
194. Zhao Y., et al. YAP-induced resistance of cancer cells to antitubulin drugs is modulated by a Hippo-independent pathway. Cancer Res. 2014, 74:4493-4503.
195. Yang S., et al. CDK1 phosphorylation of YAP promotes mitotic defects and cell motility and is essential for neoplastic transformation. Cancer Res. 2013, 73:6722-6733.
196. Basu S., et al. Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. Mol. Cell 2003, 11:11-23.
197. Wu H., et al. Integration of Hippo signalling and the unfolded protein response to restrain liver overgrowth and tumorigenesis. Nat. Commun. 2015, 6:6239.
198. Jang E.J., et al. TAZ suppresses NFAT5 activity through tyrosine phosphorylation. Mol. Cell. Biol. 2012, 32:4925-4932.
199. Zhong W., et al. Mesenchymal stem cell and chondrocyte fates in a multishear microdevice are regulated by Yes-associated protein. Stem Cells Dev. 2013, 22:2083-2093.
200. Shao D., et al. A functional interaction between Hippo-YAP signalling and FoxO1 mediates the oxidative stress response. Nat. Commun. 2014, 5:3315.
201. Wang W., et al. AMPK modulates Hippo pathway activity to regulate energy homeostasis. Nat. Cell Biol. 2015, 17:490-499.
202. Mo J.S., et al. Cellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway. Nat. Cell Biol. 2015, 17:500-510.